PMID

Data

Article Title

Organization

Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature.

University of Strathclyde

"Hit" to lead optimization and chemoinformatic studies for a new series of Autotaxin inhibitors.

Bioinnovation Institute

Recent research advances in ATX inhibitors: An overview of primary literature.

Weifang Medical University

Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry.

X-Chem

Identification of Potent

The University of Tokyo

Repurposing Suzuki Coupling Reagents as a Directed Fragment Library Targeting Serine Hydrolases and Related Enzymes.

Takeda California

Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fib

Galapagos

Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.

National and Kapodistrian University of Athens

Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Galapagos

Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe.

The University of Tokyo